Related Experiment Video
Updated: Aug 16, 2026
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Osteoprotegerin deficiency aggravates methionine-choline-deficient diet-induced nonalcoholic steatohepatitis in mice
Shaobo Wu1,2, Yao Wu3, Lan Lin3
1The Center of Clinical Research of Endocrinology and Metabolic Diseases in Chongqing, Chongqing University Three Gorges Hospital, Chongqing, 404100, China.
Abstract:
Clinical studies have shown that osteoprotegerin (OPG) is reduced in patients with nonalcoholic steatohepatitis (NASH), but the underlying mechanisms are unclear. The current study focuses on the role of OPG in the NASH pathogenesis. OPG knockout mice and wild-type control mice fed a methionine choline-deficient diet (MCD) for 4 weeks resulted in an animal model of NASH. Measurement of triglycerides (TG) in serum and liver to assess steatosis. Hematoxylin eosin (HE), Sirius Red and Masson staining were used to assess the liver damage. Transcriptome sequencing analysis, qPCR and western blot were to analyze changes in lipid metabolism and inflammation-related indicators in the liver. In vivo knockout of OPG resulted in a reduction of TG levels in the liver and a significant increase in serum ALT and AST. The expression of inflammatory factors and fibrosis genes was significantly upregulated in the livers of OPG knockout mice. Transcriptome sequencing analysis showed that OPG knockout significantly enhanced MCD diet-induced activation of the mitogen-activated protein kinase (MAPK) signaling pathway. Mechanistically, OPG may inhibit MAPK signaling pathway activity by upregulating the expression of dual specificity phosphatase 14 (DUSP14), thereby reducing inflammatory injury. OPG could regulate the activity of the MAPK signaling pathway via DUSP14, thus regulating the expression of some inflammatory factors in NASH, it may be a promising target for the treatment of NASH.
Insights
Osteoprotegerin (OPG) deficiency exacerbates nonalcoholic steatohepatitis (NASH) by activating the MAPK pathway, increasing inflammation and fibrosis. Restoring OPG may offer a therapeutic strategy for NASH treatment.
Area of Science:
- Hepatology
- Molecular Biology
- Immunology
Background:
- Osteoprotegerin (OPG) levels are decreased in nonalcoholic steatohepatitis (NASH) patients.
- The precise mechanisms linking OPG to NASH pathogenesis remain largely unknown.
Purpose of the Study:
- To investigate the role of OPG in the development and progression of NASH.
- To elucidate the molecular mechanisms by which OPG influences NASH pathology, particularly lipid metabolism, inflammation, and fibrosis.
Main Methods:
- Established a NASH animal model using OPG knockout and wild-type mice fed a methionine choline-deficient (MCD) diet for 4 weeks.
- Assessed steatosis via serum and liver triglyceride (TG) measurements.
- Evaluated liver damage using Hematoxylin eosin (HE), Sirius Red, and Masson staining.
- Analyzed hepatic lipid metabolism and inflammation using transcriptome sequencing, qPCR, and Western blot.
Main Results:
- OPG knockout mice exhibited reduced liver TG levels but significantly elevated serum ALT and AST.
- Significant upregulation of inflammatory factors and fibrosis genes was observed in the livers of OPG knockout mice.
- Transcriptome analysis revealed that OPG deficiency enhanced MCD diet-induced activation of the mitogen-activated protein kinase (MAPK) signaling pathway.
- OPG was found to inhibit MAPK signaling by upregulating dual specificity phosphatase 14 (DUSP14), thereby reducing inflammatory injury.
Conclusions:
- OPG plays a protective role in NASH by regulating the MAPK signaling pathway through DUSP14.
- OPG modulates the expression of inflammatory factors, suggesting its potential as a therapeutic target for NASH.
